丸美生物
(603983)
| 流通市值：165.45亿 | | | 总市值：165.45亿 |
| 流通股本：4.01亿 | | | 总股本：4.01亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 846,648,701.63 | 2,969,770,566.54 | 1,952,334,354.86 | 1,352,290,860.56 |
| 营业收入 | 846,648,701.63 | 2,969,770,566.54 | 1,952,334,354.86 | 1,352,290,860.56 |
| 二、营业总成本 | 684,279,945.76 | 2,610,212,848.29 | 1,695,030,314.16 | 1,145,366,644.61 |
| 营业成本 | 202,740,941.83 | 781,028,905.06 | 495,337,723.68 | 342,428,802.73 |
| 税金及附加 | 6,454,631.6 | 26,499,988.87 | 15,656,221.46 | 10,785,943.49 |
| 销售费用 | 441,717,448.89 | 1,634,676,977.95 | 1,070,923,971.2 | 717,488,735.96 |
| 管理费用 | 24,533,886.45 | 108,516,380.48 | 71,245,044.39 | 46,472,784.73 |
| 研发费用 | 15,927,066.39 | 73,544,828.78 | 54,437,089.25 | 35,846,431.69 |
| 财务费用 | -7,094,029.4 | -14,054,232.85 | -12,569,735.82 | -7,656,053.99 |
| 其中:利息费用 | 866,083.3 | 9,857,665.96 | 3,999,508.09 | 2,533,919.85 |
| 其中:利息收入 | 7,992,870.12 | 24,411,967.64 | 16,955,830.06 | 10,698,068.69 |
| 加:公允价值变动收益 | 189,317.92 | -982,898.54 | 865,061.64 | 599,493.15 |
| 加:投资收益 | 1,526,876.83 | 20,024,755.1 | 17,553,215.76 | 12,904,863.28 |
| 资产处置收益 | 382,013.03 | 29,631.89 | -206,138.86 | 892.04 |
| 资产减值损失(新) | -819,952.73 | -12,233,506.16 | -5,867,164.27 | -5,592,703.1 |
| 信用减值损失(新) | -225,474.27 | 159,077.08 | -340,917.71 | -726,234.9 |
| 其他收益 | 2,562,014.1 | 14,382,032.6 | 12,830,749.94 | 10,537,708.06 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 165,983,550.75 | 380,936,810.22 | 282,138,847.2 | 224,648,234.48 |
| 加:营业外收入 | 175,884.7 | 325,605.08 | 180,610.17 | 50,265.04 |
| 减:营业外支出 | 7,947.65 | 605,906.34 | 159,231.04 | 38,668.98 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 166,151,487.8 | 380,656,508.96 | 282,160,226.33 | 224,659,830.54 |
| 减:所得税费用 | 30,953,790.62 | 38,292,618.64 | 42,371,542.44 | 47,631,810.98 |
| 六、净利润 | 135,197,697.18 | 342,363,890.32 | 239,788,683.89 | 177,028,019.56 |
| 持续经营净利润 | 135,197,697.18 | 342,363,890.32 | 239,788,683.89 | 177,028,019.56 |
| 归属于母公司股东的净利润 | 135,045,089.33 | 341,628,707.73 | 238,803,261.67 | 176,537,086.78 |
| 少数股东损益 | 152,607.85 | 735,182.59 | 985,422.22 | 490,932.78 |
| (一)基本每股收益 | 0.34 | 0.85 | 0.6 | 0.44 |
| (二)稀释每股收益 | 0.34 | 0.85 | 0.6 | 0.44 |
| 八、其他综合收益 | -59,597.35 | -124,364.71 | -53,319.78 | -12,121.29 |
| 归属于母公司股东的其他综合收益 | -59,597.35 | -124,364.71 | -53,319.78 | -12,121.29 |
| 九、综合收益总额 | 135,138,099.83 | 342,239,525.61 | 239,735,364.11 | 177,015,898.27 |
| 归属于母公司股东的综合收益总额 | 134,985,491.98 | 341,504,343.02 | 238,749,941.89 | 176,524,965.49 |
| 归属于少数股东的综合收益总额 | 152,607.85 | 735,182.59 | 985,422.22 | 490,932.78 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-26 | 2024-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |